ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE…
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the…
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:…
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure
ZUG, Switzerland, July 23, 2025 /PRNewswire/ -- Berlin Heals and the C-MIC II…
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET | Source: Scancell Holdings Plc SCOPE trial…
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tbingen
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET | Source: Instil Bio US phase 1…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…